Treatment-resistant depression: therapeutic trends, challenges, and future directions by Al-Harbi, Khalid Saad
© 2012 Al-Harbi, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2012:6 369–388
Patient Preference and Adherence
Treatment-resistant depression: therapeutic 
trends, challenges, and future directions
Khalid Saad Al-Harbi
Medical College, King Saud Bin 
Abdulaziz University for Health 
Sciences, King Abdulaziz Medical City, 
Riyadh, Kingdom of Saudi Arabia
Correspondence: Khalid Saad Al-Harbi 
Medical College, King Saud Bin Abdulaziz  
University for Health Sciences,  
King Abdulaziz Medical City,  
Riyadh, Kingdom of Saudi Arabia 
Tel +966 1252 0088 
Email ks-alharbi@hotmail.com
Background: Patients with major depression respond to antidepressant treatment, but 10%–30% 
of them do not improve or show a partial response coupled with functional impairment, poor 
quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. 
The aim of this paper is to review the therapeutic options for treating resistant major depressive 
disorder, as well as evaluating further therapeutic options.
Methods: In addition to Google Scholar and Quertle searches, a PubMed search using key words 
was conducted, and relevant articles published in English peer-reviewed journals (1990–2011) 
were retrieved. Only those papers that directly addressed treatment options for treatment-resistant 
depression were retained for extensive review.
Results: Treatment-resistant depression, a complex clinical problem caused by multiple risk 
factors, is targeted by integrated therapeutic strategies, which include optimization of medica-
tions, a combination of antidepressants, switching of antidepressants, and augmentation with 
non-antidepressants, psychosocial and cultural therapies, and somatic therapies including elec-
troconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, 
deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. As 
a corollary, more than a third of patients with treatment-resistant depression tend to achieve 
remission and the rest continue to suffer from residual symptoms. The latter group of patients 
needs further study to identify the most effective therapeutic modalities. Newer biomarker-based 
antidepressants and other drugs, together with non-drug strategies, are on the horizon to address 
further the multiple complex issues of treatment-resistant depression.
Conclusion: Treatment-resistant depression continues to challenge mental health care provid-
ers, and further relevant research involving newer drugs is warranted to improve the quality of 
life of patients with the disorder.
Keywords: treatment-resistant depression, antidepressants, biomarkers, therapeutic options, 
somatic therapies
Introduction
Major depression is a common debilitating disorder affecting 10%–15% of the 
population per year. Despite advances in the understanding of the psychopharmacology 
and biomarkers of major depression and the introduction of several novel classes of 
antidepressants, only 60%–70% of patients with depression respond to antidepressant 
therapy. Of those who do not respond, 10%–30% exhibit treatment-resistant symptoms 
coupled with difficulties in social and occupational function, decline of physical health, 
suicidal thoughts, and increased health care utilization. Treatment-resistant depres-
sion represents a dilemma for health care providers. Major depression with a poor or 
unsatisfactory response to two adequate (optimal dosage and duration) trials of two 
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different classes of antidepressants has been proposed as an 
operational definition of treatment-resistant depression.1–4
It is reported that at any one time 14 million people suffer 
from depression, and only 50% of them receive some form 
of treatment. Up to 70% of people who have depression 
show substantial improvement as measured by commonly 
used rating scales, such as the Hamilton Rating Scale for 
Depression (HRSD),5,6 but they require additional psycho-
social interventions for achieving complete remission. It is 
estimated that 10%–30% of patients with major depression 
do not respond to typical antidepressant medications,7 and 
this group of patients needs trials of a variety of treatment 
  strategies. For this purpose, it is particularly important to 
determine the adequacy and outcome of prior treatment   trials 
by using the Antidepressant Treatment History Form that 
helps to exclude “pseudoresistance” cases.8 Complete remis-
sion is achieved in 70%–90% of patients with depression, 
leaving 10%–30% refractory to treatment, and managed by 
a variety of therapeutic modalities. Unfortunately, approxi-
mately 30% of patients with treatment-resistant depression 
do not respond to any treatment.9,10
According to the findings from the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study, 
50%–66% of patients with depression do not recover fully 
on an antidepressant medication and one-third of patients 
do have a remission of their depressive symptoms.11,12 
It is obvious that use of a variety of treatment approaches 
versus only an antidepressant makes the outcome variable 
in patients with major depression. Notably, the results of 
mega STAR*D studies open windows into the effective-
ness or ineffectiveness of antidepressant medications among 
patients seeking treatment in real-world settings, including in 
primary health care13,14 and help clinicians to make treatment 
decisions in patients with treatment-resistant depression. 
The prevalence of both treatment-resistant depression and 
non-treatment-resistant depression would impressively be 
variable across time attributed to methodological issues, defi-
nition of treatment-resistant depression, and the therapeutic 
options used, including neurostimulation therapies.
Treatment-resistant depression defies true definition9 
(Table 1), but mental health experts agree that it should 
only be diagnosed in patients who have not been helped 
by two or more antidepressant treatment trials of adequate 
dose and duration. To add difficulty to the definition of 
treatment-resistant depression, treatment response and suc-
cess has different meanings across multiple research settings. 
By and large, treatment-resistant depression evades universal 
definition and meaning, and poses a number of diagnostic 
Table 1   Suggested  terminology  for  treatment-resistant 
depression9
Treatment  
non-response
A response that is poor enough with significant 
residual symptoms that a change in the treatment 
plan is called for (eg, failure to evidence at least a 
50% reduction in the HRSD score
Treatment  
response
A response that is good enough that a change in 
the treatment plan is not usually called for  
(eg, at least a 50% reduction in HRSD score)
Remission Attainment of a virtually asymptomatic status 
(eg, HRSD 7) for at least 2 consecutive weeks
Recovery Remission for 6 consecutive months
Relative treatment  
resistance
Non-response to an adequate dose of a 
potentially effective medication for an adequate 
length of time
Absolute treatment  
resistance
Failure to respond to a maximal trial of a single 
treatment for an extended period of time  
(eg, imipramine at 300 mg/day for 6 weeks)
Treatment-refractory  
depression
Treatment non-response (ie, persistence of 
significant depressive symptoms) despite at least 
two treatment trials with drugs from different 
pharmacological classes, each used in an 
adequate dose for an adequate time period
Adequate dose An oral dose that is close to the manufacturers’ 
recommended maximal dose. Adequate dose 
may be smaller for elderly patients
Adequate length  
of treatment
At least 4 consecutive weeks of treatment, 
during which the patient has had an adequate 
dose for at least 3 weeks
Medication  
intolerance
inability to achieve or maintain an adequate 
therapeutic dose of an antidepressant drug due 
to idiosyncratic reactions or side effects9
Abbreviation: HRSD, Hamilton Rating Scale for Depression.
and therapeutic challenges to mental health experts. The aim 
of this paper is to review the therapeutic options for treating 
resistant major depressive disorder, as well as evaluating 
further therapeutic interventions.
Search methods
In addition to Google Scholar and Quertle websites, literature 
searches were also conducted using PubMed for the years 
1990–2011 and entering the keywords “treatment-resistant 
depression”, “treatment-refractory depression”, “partial 
response depression”, and “nonresponsive depression”. 
These words were combined with tricyclic antidepressants 
(TCA), selective serotonin reuptake inhibitors (SSRI), 
serotonin norepinephrine reuptake inhibitors (SNRI), 
and atypical antipsychotics, somatic therapies, such as 
electroconvulsive therapy (ECT), vagus nerve stimulation 
(VNS), deep brain stimulation (DBS), repetitive transcranial 
magnetic stimulation (rTMS), magnetic seizure therapy, 
transcranial direct current stimulation (tDCS), and 
psychotherapy for a second round of computer searching. 
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Another round of searching included a combination 
of keywords, ie, “treatment-resistant depression with 
augmentation strategies”, “combined antidepressants”, 
“switching approaches”, “names of individual antidepressant 
medications”, and “nonpharmacological interventions”. As a 
corollary, relevant articles published in English peer-reviewed 
journals were retrieved. Only those papers including original 
studies, clinical trials, systematic reviews, and meta-analyses, 
which directly addressed treatment-resistant depression, were 
retained for extensive review and inclusion in this study. 
Some exceptions were made with regard to small case series, 
and related mainly to somatic therapies.
Therapeutic trials: pros and cons
Well designed clinical trials provide strong evidence-based 
data for antidepressant therapy for treatment-resistant depres-
sion, but there are many difficulties in interpreting their 
results. There is no absolutely correct dosage for a specific 
antidepressant, because dosage requirements vary with age, 
gender, weight, physical health, concomitant medication 
usage, and tolerance. Confirmation of treatment adequacy by 
serial plasma drug levels is not the rule in clinical practice, 
and valid plasma level-response relationships are   limited 
to only a subgroup of TCA and lithium,9 and are now 
extended to certain newer antidepressants. In a study that 
examined the relationship between plasma antidepressant 
concentration and both clinical response and adverse effects 
in treatment-resistant depressed adolescents, 334 participants 
with major depression who had not responded to an SSRI 
were randomized to one of four treatments, ie, switch to 
another SSRI (fluoxetine, citalopram, or paroxetine), switch 
to venlafaxine, switch to SSRI + cognitive behavior therapy, 
or switch to venlafaxine + cognitive behavior therapy. 
Adolescents who did not improve by 6 weeks had their 
dose increased. Plasma concentrations of medication and 
metabolites were measured at 6 weeks in 244 participants 
and at 12 weeks in 204 participants.
Adolescents treated with citalopram whose plasma con-
centration was equal to or greater than the geometric mean 
showed a higher response rate compared with those having 
less than the geometric mean, with parallel but nonsignificant 
findings for fluoxetine. A dose increase of citalopram or fluox-
etine at week 6 was most likely to result in a response when it 
led to a change in concentration from less than the geometric 
mean at 6 weeks to the geometric mean or greater at week 12. 
Plasma levels of paroxetine, venlafaxine, or O-desmethylven-
lafaxine were not related to clinical response. Exposure was 
associated with more cardiovascular and dermatologic side 
effects in those receiving venlafaxine. It was concluded that 
the antidepressant concentration may be useful in optimiz-
ing treatment for depressed adolescents receiving fluoxetine 
or citalopram.15 With respect to psychotherapy, adequacy of 
treatment may depend on the number of sessions, the expertise 
of the practitioner, the therapist’s adherence to a particular 
form of therapy, and also interaction within the patient-
therapist dyad. The efficacy of ECT trials may be gauged by 
the total number of treatments, the use of bilateral electrode 
placement, and verification of seizure occurrence and its 
timing by electroencephalographic monitoring. Therefore, 
treatment resistance is linked to a certainty about the adequacy 
of a specific treatment trial.16–19
Researchers have categorized treatment-resistant 
depression in accordance with antidepressant trials as: stage 0,   
has not had a single adequate trial of medication; stage 1, 
failure of an adequate trial of one class of an antidepressant, 
ie, monotherapy; stage 2, failure of adequate trials of 
two distinctly different classes, ie, an SSRI and TCA, as 
two monotherapy trials; stage 3, stage 2 plus failure to 
respond to one augmentation strategy, ie, lithium or thyroid 
augmentation of one of the monotherapies; stage 4, stage 3 
plus a failure on a second augmentation strategy in terms 
of monoamine oxidase inhibitors; and stage 5, stage 4 plus 
failure of an adequate course of ECT.9 There are other staging 
methods for treatment-resistant depression, including the 
Antidepressant Treatment History Form, the Thase and Rush 
model, the European Staging model, the Massachusetts 
General Hospital Staging model, and the Maudsley Staging 
model, with variable predictive validity and reliability.20 
These staging methods help researchers and clinicians to 
understand the severity and chronicity of treatment-resistant 
depression and plan trial interventions accordingly.
Patient concerns
Treatment-resistant depression is a difficult condition to 
treat. Patients with the disorder should interactively share 
their inner experiences with the treating expert and be able 
to ask freely any questions related to risk factors underlying 
treatment-resistant depression, better treatment options, 
lifestyle changes, costs and insurance coverage, a proper 
medication schedule, duration of treatment, severity of side 
effect, suicidal thoughts and attempts, non-suicidal self-
injurious behaviors, and intolerance issues. Other related 
issues to be discussed with patients having treatment-
resistant depression are adherence to treatment, impact 
of medical comorbidities such as heart disease, cancer, 
thyroid disease, anemia, and eating disorders, interactions 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
371
Treatment-resistant depressionPatient Preference and Adherence 2012:6
between antidepressants and other medications including 
herbal supplements, manifestations of impending relapse, 
and genetic vulnerability. Mental health experts should also 
address in nontechnical language patients’ concerns about 
somatic therapies, including ECT, VNS, tDCS, rTMS, 
magnetic seizure therapy, and DBS.12,19
Patients with treatment-resistant depression should 
know about the predictors of good and bad outcomes of 
treatment. In a UK study that aimed to assess the impact 
of post-treatment clinical states on longer-term outcome 
recruited 118 patients with treatment-resistant depression 
who received specialist inpatient treatment and were followed 
up for a median of 3 years. Longitudinal outcome, dichoto-
mized into good and poor, was used as the primary outcome 
and functional measures were used as secondary outcomes. 
Among the 118 treated patients, 40 (34%) entered clinical 
remission, 36 (31%) entered partial remission, and 42 (37%) 
remained in a depressive episode at discharge. At follow-up, 
35% had a longitudinally defined poor outcome. According 
to this study, post-treatment clinical status was the main 
predictor of both poor and good outcome. Nearly 50% of 
patients achieved post-discharge recovery, and subsequently 
had a longer-term outcome comparable with that of patients 
discharged in remission. Patients who remained in an episode 
post-treatment were more symptomatically and functionally 
impaired. In summary, post-treatment clinical states are 
a useful guide for clinicians in projecting the longer-term 
outcome for patients with treatment-resistant depression. The 
persistence of residual or syndromal symptoms predicts a 
poorer longer-term outcome, whereas treatment to remission 
is associated with better outcomes.21
In another study of young adolescents with SSRI-resistant 
depression, suicide attempts and nonsuicidal self-injuries 
were found to have clinical and prognostic significance. 
This research further called for preventive and therapeutic 
strategies for treatment-resistant depression and its associated 
adverse behavioral complications.22 Patients with treatment-
resistant depression also need to be familiar with issues 
related to weight gain.23 Like patients with depression and 
general medical conditions,24 patients with treatment-resistant 
depression also have cost concerns associated with variable 
outcomes and poor adherence to treatment or combined 
therapies. Patients with depression who respond/remit on 
antidepressant treatment bear less cost than those who have 
persistent depression.25,26 By and large, treatment-resistant 
depression is associated with extensive use of depression-
specific and general medical services, which poses a sub-
stantial economic burden, together with work loss costs.27,28 
In a related context, a randomized, controlled trial evaluated 
the incremental cost-effectiveness over 24 weeks of combined 
cognitive behavior therapy plus a switch to a different 
antidepressant medication versus a medication switch only 
in adolescents who continued to have depression despite 
adequate initial treatment with an SSRI. Participants were 
randomly assigned to switch to a different medication 
only or to switch to a different medication plus cognitive 
behavior therapy. Clinical outcomes were depression-free 
days, depression-improvement days, and quality-adjusted 
life-years based on depression-free days. It was revealed that 
combined treatment had a higher net benefit for subgroups 
of youth without a history of substance abuse, with lower 
levels of hopelessness, and with comorbid conditions. For 
youth with SSRI-resistant depression, combined treatment 
decreases the number of days with depression and was more 
costly. It was concluded that, depending on a decision-maker’s 
willingness to pay, combined therapy may be cost-effective, 
particularly for some subgroups.29
Risk factors
There is no one reason for treatment-resistant depression. 
Depression is a heterogeneous disorder, as reflected by treat-
ment heterogeneity and variable nonresponse rates,30 and the 
latter could be due to patient age and gender. Elderly patients 
may be somewhat less treatment-responsive than those at 
midlife. Conversely, younger women may benefit less from 
TCA than men or women treated with monoamine oxidase 
inhibitors.9 Individuals with fewer interpersonal or economic 
resources, minority status, lower function and quality of 
life, and chronic depression may also be less responsive 
to antidepressant treatment. Furthermore, a higher level of 
objective stress, poorer social support and family networks, 
and/or a greater risk of noncompliance also contribute 
to treatment-resistant depression.9,31,32 However, for most 
patients with treatment-resistant depression, it is probably 
a combination of different risk factors (Table 2) which are 
as follows: not staying on prescribed antidepressants long 
enough, ie, for 6–12 weeks when they have their full effect; 
skipping doses, in terms of poor adherence (blood sample 
analysis for measuring drug levels is an option for confirming 
or excluding such a possibility); unpleasant side effects of 
prescribed psychiatric and non-psychiatric drugs; drug–drug 
interactions in particular antidepressants and medical 
treatments; the wrong medicine or the wrong dose for the 
individual in question; genetic disposition in terms of fast 
or slow metabolizers of antidepressants; medical comorbid 
conditions, such as hypothyroidism and anemia, which also 
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contribute to depression by several mechanisms and each 
needs a separate treatment approach, and ignoring either 
of them would result in treatment failure and nihilism; and 
eating disorders, alcohol, and other substance-use disorders, 
which tend to worsen the depression or might be the main 
underlying cause of depression.9,32 Furthermore, break-
through episodes can also occur among patients partially or 
fully improved that may contribute to the resistant nature of 
depression.33 In addition, misdiagnosis of depression also 
leads to treatment-resistant depression.34 Misdiagnosis also 
includes failure to identify the actual subtype of depres-
sion, such as atypical, psychotic, bipolar, or melancholic 
depression, that has an impact on treatment selection and 
outcome and may require concurrent pharmacotherapy, 
such as an antipsychotic or augmentation psychotherapy.9 
Some evidence also indicates a poorer response to TCA in 
atypical depression, bipolar depression, psychotic depression, 
and depression associated with significant Axis I, Axis II, or 
Axis III comorbidity.31 Further, major depressive disorder that 
remains unrecognized and untreated may become treatment-
resistant depression.35
Another symptomatic correlate of treatment resistance 
is the global severity of depression. A naturalistic study 
revealed that most patients with a substantial degree of 
treatment resistance continue to have significant symptoms 
and functional disability when receiving their usual 
treatment.36 Finally, the adverse effects of medication and 
poor compliance determined by poverty and low education 
may be additional obstacles to successful treatment of 
depression.19,37,38 According to the World Health Organization 
International Classification of Functioning, Disability and 
Health, that includes psychiatric disorders,39 including 
major depression and treatment-resistant depression, 
the participation level of patients with depression is an 
important treatment component that may influence their 
outcomes and correspondingly might contribute to treatment-
resistant depression. Interestingly, based on the perceived 
relative therapeutic efficacy of available treatment options, 
depression may also be seen as a secondary compliance 
risk factor for treatment-resistant depression. In a recent 
review, risk factors for treatment-resistant depression in 
adolescents were identified to be the severity of depression, 
level of hopelessness and suicidal ideation, psychiatric 
and medical comorbidities, environmental factors such as 
family conflict, maternal depression, and history of physical 
and sexual abuse, as well as pharmacokinetics and other 
biomarkers.40,41
In another study, a team of researchers reported that 
genetic polymorphisms in the transcription factor, cyclic ade-
nosine monophosphate response element binding (CREB1), 
could be associated with treatment resistance in patients 
with depression.42 Also, based on an experimental animal 
study,43 researchers reported discovering a mutant gene on 
chromosome 12 that codes for tryptophan hydroxylase-2. 
This enzyme helps in the biosynthesis of serotonin, and is 
produced 80% less than normal by individuals with major 
or treatment-resistant depression who have this mutant gene, 
which was also identified in normal individuals (3/219), 
but much less often than in patients with severe depression 
(9/87).44 The implication of this study is that genetic test-
ing, if developed, could identify patients with depression 
who would or would not respond satisfactorily to one of the 
antidepressants, eg, a TCA, SSRI, or SNRI.
Table 2 Risk factors for treatment-resistant depression
Risk factors Remarks
Not staying on a  
medicine long enough
Antidepressants can take as long as 6–8 
weeks before they fully take effect
Skipping doses Take depression medicine exactly as 
prescribed to know it is working effectively
Unpleasant side effects Consult doctor for emerging side effects of 
antidepressants because he/she may offer 
some help including informing that side 
effects tend to decrease over time
Drug interactions Some medicines do not work well 
with antidepressants and in some cases 
interactions with dangerous consequences 
may occur
wrong medicine  
or wrong dose
Antidepressant drugs work very differently 
in different people and finding the right 
medicine, at the right dose, takes trial  
and error
Genes Researchers have found a gene that 
interferes in the synthesis of tryptophan, 
a substrate for serotonin synthesis, 
deficiency of which contributes to 
treatment resistance
Co-occurring medical  
conditions
Medical conditions like heart disease, 
cancer, or thyroid problems, and eating 
disorders can contribute to depression, 
and need to be treated simultaneously
Co-occurring psychiatric  
conditions
Co-occurring Axis i and Axis ii diagnosis 
needs concurrent treatment
Alcohol or drug abuse Depression may pre- or post-cede 
substance abuse that need proper 
treatment as well
wrong diagnosis Some people are simply misdiagnosed with 
treatment-resistant depression and need 
comprehensive reassessment
Poverty and low  
education
As environmental effect sizes in affected 
individuals with treatment-resistant 
depression may negatively interfere with 
compliance
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In summary, depressive illness-related factors, personal 
characteristics, medication variables, and psychosocial 
stresses collectively contribute to the development of 
treatment-resistant depression, and are associated with a 
considerable disease burden.45
Therapeutic options
There are five main strategies (Table 3) used to overcome a 
partial response or lack of response to antidepressant therapy, 
ie, optimization, switching, combination, augmentation, and 
somatic therapies.46 Because there is no standard treatment 
approach, mental health experts offer the aforesaid strategies 
based on re-evaluation of patients with treatment-resistant 
depression. The patient with depression not responding to 
antidepressant monotherapy requires a highly individualized 
treatment plan and, accordingly, some people will respond 
to a specific treatment, while others do not. Finding the 
right approach to treat depression can take a lot of effort 
and time.29,30 Therefore, the following principles need to 
be followed to manage patients with treatment-resistant 
depression: ensure accurate diagnosis, including subtype 
of depression; assess comorbid psychiatric and medical 
conditions; evaluate psychosocial stressors, as well as social 
and family support; ensure adequate dose and duration of 
treatment; monitor and treat adverse events; educate the 
patient regarding depression and antidepressants; ensure 
compliance; and aim for remission. The five approaches are 
now described briefly.
Optimization of antidepressants
The two core features of this strategy are to optimize dosage 
and duration of antidepressant therapy for patients who have 
experienced only partial improvement. The advantages of this 
strategy are to capitalize on the natural history of episodic 
depression which remits over time and to counteract the 
tendency of some patients to discontinue the antidepressant 
prematurely. Furthermore, it helps to distinguish a true 
enduring antidepressant response from a more transient 
placebo response. Specifically, placebo responders have a 
greater likelihood of relapse between weeks 6 and 12 than 
patients who have responded to active antidepressants.9,32 
An adequate trial of antidepressant therapy has been defined 
by some clinicians as a minimum of 6 weeks.7 If the patient 
exhibits a partial response during this initial period, another 
4–6 weeks of treatment should be added. Thus, a total of 
10–12 weeks may be required in some cases to elicit a full 
response to antidepressant therapy.47 Irrational prescribing 
of antidepressant medications with regard to dosage and 
duration is a common cause of treatment failure9,47 and 
is common in clinical practice. In a study conducted in a 
managed care environment, only 11% of patients requiring 
antidepressant therapy received either an adequate dosage 
or duration of therapy.48 This irrational prescribing trend is 
particularly common in elderly patients,49 and is especially 
problematic in low-income and middle-income countries. 
The older literature suggests that routine prescription of 
maximal doses of TCA, monoamine oxidase inhibitors, and 
second-generation antidepressants is associated with a greater 
likelihood of response than more modest doses in patients 
with treatment-resistant depression.9 Notably, administration 
Table 3 Management strategies for treatment-resistant depression
Therapeutic strategies  
and options
Remarks
Optimization  
of antidepressants
Maximize dose for adequate time 
and check serum levels of prescribed 
antidepressant if supported by evidence-
based data
Switching  
of antidepressants
Changing from one ineffective 
antidepressant to similar or different 
class of antidepressant; SSRi/SNRi to 
TCA, MAOi, and atypical antipsychotics 
with antidepressant properties
Combination  
of antidepressants
Adding another antidepressant from 
different classes, eg, TCA + MAOi,  
SSRi + TCA, SSRi + atypical 
antidepressant, SSRi + buspirone, etc
Augmentation  
strategies
Adding a second agent that is not 
an antidepressant but may enhance 
the antidepressant effect of the 
drug in question, eg, lithium, thyroid 
hormones, pindolol, psychostimulants, 
atypical antipsychotics, sex hormones, 
anticonvulsants/mood stabilizers, and 
dopamine agonists
Somatic therapies ECT, vNS, rTMS, MST, DBS, and TDCS
integrated approach Use of antidepressants together with 
other modes of treatment, which 
include psychotherapy, risk management 
strategies, CAM therapies, and life style 
changes such as exercise and school 
vacation
Adjunctive approach Use of a treatment to manage the side 
effects of antidepressants and also to 
increase its efficacy
Neurosurgical  
interventions
isolated, severe cases of treatment-
resistant depression
Continuing research in genetic, biomarkers, and animal models 
for drug development
Abbreviations: CAM, complementary and alternative medicine; TDCS, transcranial 
direct  current  stimulation;  ECT,  electroconvulsive  therapy;  vNS,  vagus  nerve 
stimulation;  rTMS,  repetitive  transcranial  magnetic  stimulation,  DBS,  deep  brain 
stimulation; MST, magnetic seizure therapy; TCA, tricyclic antidepressant; MAOi, 
monoamine oxidase inhibitors; SSRi, selective serotonin reuptake inhibitor; SNRi, 
serotonin-norepinephrine reuptake inhibitor.
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of higher doses of first-generation and second-generation 
antidepressants in patients with treatment-resistant depres-
sion requires monitoring of blood levels to track the clinical 
response and to avoid adverse effects.
Switching strategies
The switching approach mainly involves discontinuing an 
ineffective antidepressant and starting a new antidepressant 
from a similar or different class in patients with treatment-
resistant depression. Earlier studies found response rates 
of only 10%–30% for TCA in patients with a past history 
of lack of response to TCA.9 A trial course of nortriptyline 
guided by plasma levels similarly suggested a 30% response 
in patients with a prior history of TCA failure.50 Conversely, 
better response rates of up to 70% have been reported when 
patients are switched to an alternative class of antidepressant, 
including the second-generation heterocyclic antidepres-
sants and SSRI/SNRI coupled with a different mechanism 
of action.7,30,32,47 Thase and Rush reviewed the relevant 
literature on old trend switching approaches involving 
several within and across classes of antidepressants in the 
population with treatment-resistant depression and similar 
conclusions were drawn, with the recommendation to conduct 
larger, controlled, double-blind, crossover studies of SSRI/
SNRI-resistant depression using newer antidepressants and 
TCA.9 A number of relatively well designed studies,51–67 
which focused on switching strategies from SSRI in major 
depression, have been conducted to address these issues, and 
are summarized in Table 4. A summary of the findings of 
these studies is as follows: response rate 26%–76%; remis-
sion rate 28%–87%; a TCA might prove to be a strategy 
of first choice for patients who do not respond to an SSRI; 
intolerance to one SSRI does not necessarily mean intoler-
ance to the whole class of SSRI; challenges include collecting 
controlled data to address the equally important question 
about the effectiveness of an alternate SSRI when another 
member of this class is not effective; across-class switch is 
a good treatment option; in patients unresponsive to SSRI, 
administration of antidepressants with different mechanisms 
of action is an effective switching strategy; and switching 
from an SSRI to a TCA and vice versa in patients who do not 
respond to a 4-week trial is not associated with an improved 
response. The last observation runs counter to that predicted 
by current guidelines.68
The advantages of this strategy are improved adherence, 
reduced medication costs, and fewer drug interactions,69 
while the disadvantages are that therapeutic gains from 
original antidepressant are lost, the patient has to wait for 
the new agent to become effective, and relapse or withdrawal 
symptoms together with adverse effects may occur during 
the intervening period. This is particularly true if the 
half-life of the first agent is quite long, as is the case with 
fluoxetine (35 days), and another SSRI is started before an 
adequate washout period has occurred. Other antidepressants 
that require longer washout periods of up to 14 days are 
clomipramine, tranylcypromine, moclobemide, bupropion, 
and phenelzine if switched to another TCA, monoamine 
oxidase inhibitor, or SSRI. Serotonin syndrome,70 reflecting 
toxic serotonin levels in the central nervous system and 
characterized by hyperalertness, agitation, confusion, 
restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, 
tremor, and, possibly, death, may occasionally develop if the 
washout period was inadequate when switching from one 
SSRI antidepressant to another. In summary, the risks of 
toxicity are greater with higher dosage regimens and an inad-
equate washout period, although urgent cases may necessitate   
a shorter switching interval.
Combination of antidepressants
Combination therapy involves the addition of a second anti-
depressant agent from a different class to the therapeutic 
regimen of patients with treatment-resistant depression.30,71 
The additional antidepressant is used for 12 weeks or even 
months in optimum doses.9 Older antidepressants may 
be used because they are reported to have good results in 
treatment-resistant depression coupled with severe, recurrent 
depression.72–74 Various types of combination are reported in 
the literature, but the most common are TCA + SSRI followed 
by, eg, venlafaxine + TCA, SSRI + SSRI, and SSRI + venla-
faxine.75   Venlafaxine + mirtazapine is frequently used in 
clinical practice, and this combination produces a good 
response in patients with difficult-to-treat depression, which 
is attributed to the synergistic action of this combination. In 
one study of 32 patients with persistent depressive illness, 
the mirtazapine + venlafaxine combination was given at 
some point over a 3-year period between 2002 and 2005. 
Clinical response rates were 44% at 4 weeks and 50% at 8 
weeks. At 6-month review, 56% of the original cohort and 
75% of those still receiving treatment had shown a sig-
nificant response. In total, 44% experienced some adverse 
effects. Five patients discontinued treatment due to seda-
tion (19%) and weight gain (19%).76 In another study, the 
venlafaxine + mirtazapine combination was given to 22 
patients with major depression who had failed one trial 
of antidepressant therapy. The mean duration of treat-
ment was approximately 8 weeks, producing a response 
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Table 4 Summary of clinical studies of switching from an SSRi in major depression
Reference Initial  
treatment
Post-switch  
treatment
Design Response rate
Thase et al51 Sertraline Fluoxetine n = 106, open, non-response,  
or intolerance
63%
Brown and  
Harrison52
Fluoxetine Sertraline n = 91, open, primarily  
intolerant
76%
Zarate et al53 Fluoxetine Sertraline n = 31, open, non-response  
or intolerance
42% at discharge, 
26% at follow-up
Joffe et al54 Fluoxetine, 
Sertraline, 
Paroxetine
Second SSRi n = 55, open,  
non-response only
51%
Peselow et al55 Paroxetine imipramine n = 15, double-blind,  
prospective nonresponse
73%
Thase et al56 Sertraline imipramine n = 117, double-blind,  
cross-over prospective  
non-response
60% in the sertraline group and  
44% in the imipramine group
Nierenberg et al57 various venlafaxine n = 84, open, non-response  
to 3 prior trials
33%
De Montigny et al 58 various venlafaxine n = 152, open, nonresponse  
to at least one prior trial
58% response 
28% remission
Kaplan59 Fluoxetine, 
Sertraline, 
Paroxetine
venlafaxine n = 73, open, nonresponse  
to one prior SSRi
87% full remission
Poirer and  
Boyer60
various, two  
thirds SSRis
venlafaxine or  
Paroxetine
n = 172, double-blind,  
randomized, nonresponse to  
two prior trials, 1 prospective
Response 
52% venlafaxine, 33% paroxetine 
Remission 
42% venlafaxine, 22% paroxetine
McGrath et al61 Fluoxetine Bupropion n = 18, open, nonresponse 
to prior prospective  
fluoxetine trial
28% response
Fava et al62 various SSRi Mirtazapine n = 69, open, nonresponse 
to prior prospective SSRi trial
48% response
Thase et al63 various SSRi Mirtazapine or  
Sertraline
n = 243, double-blind,  
randomized, nonresponse 
to one prior SSRi, not sertraline
At week 3 and 4 mirtazapine . sertraline,  
P , 0.05 (.50% improvement) and at 
week 8 mirtazapine and sertraline, P = NS. 
Remission rate 37% mirtazapine  
and 29% sertraline
Rapaport et al64 SSRi, 
Citalopram
Risperidone n = 489, multiple designs,  
double-blind, placebo-controlled,  
nonresponse to 1–3 SSRi failures
Median time to relapse was 97 days  
with risperidone augmentation and  
56 with placebo (P = 0.05); relapse  
rates were 56% and 64%, respectively  
(P , 0.05)
Lenox-Smith  
and Jiang65
SSRi venlafaxine 
Citalopram
n = 406, 12-week, double-blind,  
randomized, parallel-group,  
multicenter study
venlafaxine and citalopram with similar 
efficacy. In severely depressed patients, 
venlafaxine ER was significantly more 
effective
Souery et al66 Citalopram  
Despiramine
Despiramine/ 
citalopram
n = 189, nonresponse,  
prospective study, 8 weeks
First 4 weeks, no difference between 
citalopram and despiramine or switch,  
but in the next 4 week, remitter  
rates . among non-switched patients, 
switched patients had more score on 
HRSD and MADRS, CGi scales
Rosso et al67 SSRi Duloxetine and 
bupropion
n = 49, a randomized,  
comparison study,  
2 SSRi trial failures
Response rate 60%–70% and remission 
rate 30%–40%
Copyright © 2003, Physicians Postgraduate Press. Adapted with permission from Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry. 2003;64 Suppl 1:5–12.69
Abbreviations: ER, extended-release; HRSD, Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; CGi, Clinical Global impression; 
NS, not statistically significant; SSRI, selective serotonin reuptake inhibitors.
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rate of 81.8% and a remission rate of 27.3%. Only one patient 
was unable to tolerate the combination, although 50% had 
significant side effects during treatment.77
This approach has certain disadvantages, ie, it does not 
allow for adequate evaluation of monotherapy, is associ-
ated with reduced compliance, has an increased likelihood 
of adverse effects, is prone to polypharmacy, and has the 
potential for increased drug interactions. Advantages of the 
combination approach are that it is coupled with a rapid 
response, no titration is necessary, initial improvements are 
maintained, the strategy builds on therapeutic gains, addition 
of the second compound is generally well tolerated, and the 
disadvantages of switching strategies are avoided. In addition, 
the response rate is comparable or superior to drug substitu-
tion. In this strategy, there might be a synergistic therapeutic 
effect, but side effects due to drug–drug interactions also tend 
to emerge, so careful drug surveillance is needed.6,69
Augmentation strategies
Augmentation therapy involves adding a second agent (but 
one that is not routinely regarded as an antidepressant) to the 
therapeutic regimen when there is only a partial response to 
the primary antidepressant agent.38 The reported strength of 
recommendation for augmentation or switching is best sup-
porting evidence.78 Various augmenting agents, including 
lithium, atypical antipsychotics, thyroid hormone, pindolol, 
buspirone, dopamine agonists, sex steroids, glucocorticoid-
specific agents, herbal products, and newer   anticonvulsants, 
have been used in patients with treatment-resistant 
  depression.19 Augmentation options, mechanisms, and dosing 
strategies for the various agents are summarized in Tables 5–7. 
The key points are as follows: downregulation of central 
beta-adrenergic receptors, which explains the 4–6-week 
delay in obtaining clinical improvement; lithium enhances 
not only serotonin neurotransmission but also impacts other 
neurotransmitter systems and neuromodulators, with a 
response rate of 30%–65% in patients with treatment-resistant 
depression who have failed several classes of antidepressants 
and coupled with equal augmentation efficacy at serum blood 
levels of 0.4 and 0.8 mEq/L; response may take just 2 days or 
up to 3–6 weeks, which is considerably shorter than the delay 
expected with switching, which involves taper of the first drug, 
washout, and delay in onset of the second drug; antagonism 
of 5HT2A receptors, common among atypical antipsychotics, 
is also seen with mirtazapine and nefazodone and is coupled 
with enhanced release of frontal dopamine and norepineph-
rine, which is thought to be a key action of antidepressant 
agents; fluoxetine–olanzapine reported 40%   improvement 
among patients with treatment-resistant depression as 
  compared with 30% and 25% improvement with fluoxetine 
and olanzapine alone, respectively; olanzapine, aripiprazole, 
  quetiapine, and ziprasidone had mixed results in a population 
with treatment-resistant depression; T3 25–50 µg/day for 
2–3 weeks is more effective than T4 for augmenting TCA, 
monoamine oxidase inhibitors, SSRI, and lithium in patients 
with treatment-resistant depression; monitoring thyroid 
function before T3 administration for a baseline reading as 
well as after administration is important; pindolol, a 5-HT1A 
postsynaptic antagonist, accelerates the onset of action of 
antidepressants by preventing negative feedback to the pre-
synaptic 5-HT1A receptor but is currently not recommended 
for this purpose; unlike open-label studies, buspirone is 
ineffective in randomized controlled trials; stimulants had 
no positive results in randomized controlled trials involving 
patients with treatment-resistant depression; after adjusting 
for the selection bias inherent in the STAR*D comparison 
of augmentation versus switching, clinically meaningful 
differences in the adverse event profiles between these 
strategies were not observed; risperidone (remission rate 
[RR] 26.7%), valproate (RR 48.7%), buspirone (RR 32.6%), 
trazodone (RR 42.6%), and thyroid hormone (RR 37.5%) 
added to paroxetine 20 mg/day was effective and well toler-
ated in 225 Chinese patients with stage II treatment-resistant 
depression; an add-on multicenter trial of 183 patients with 
treatment-resistant depression failed to detect a statistically 
significant difference between lamotrigine and placebo 
given for 10 weeks, but post hoc analysis suggested that 
future studies of the efficacy of lamotrigine should focus 
on specific subgroups with depression; a double-blind, 
placebo-controlled study found that topiramate augmenta-
tion potentiates the efficacy of SSRI (fluoxetine, citalopram, 
sertraline) in the treatment of resistant depression; and further 
large, comparative, double-blind, randomized clinical trials 
of augmentation agents in patients with treatment-resistant 
depression are needed.9,30,79–99
The level of evidence for common augmentation agents 
is as follows: lithium and T3 (best evidence); atypical 
antipsychotic drugs (some evidence); stimulants, inositol, 
estrogen, omega-3 fatty acids, and dopamine agonists (little 
evidence); herbal supplements, lamotrigine (no evidence); 
and tetraiodothyronine and pindolol (not effective).46
Comorbidity
Patients with treatment-resistant depression need to be 
assessed for comorbid medical and other psychiatric 
conditions. This is mandatory because 75.5% and 46.9% 
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Table 5 Augmentation options for treatment-resistant depression
Medication Available data Remarks
Traditional agents
Mirtazapine77 Positive RCTs,77 STAR*D Limited data
Bupropion100 Multiple open-label trials, RCTs, STAR*D Rapidly effective and more data are needed
Buspirone96 Negative RCTs, STAR*D ineffective in RCTs
T3 Limited RCTs with SSRi,78,96 positive  
when combined with TCA91,93
Comparable with lithium in STAR*D but fewer  
side effects
Lithium Limited RCTs with SSRi,78,80 positive when  
combined with TCA93
Comparable to T3 in STAR*D but more side effects
Lamotrigine97 Negative RCTs Small numbers, mixed populations
valproate96 Pilot RCT, effective and well tolerated Data are limited and larger sample size RCTs are needed
Topiramate98 Positive RCT98 RCTs with larger sample needed
Pindolol94 Negative RCTs94 Positive data for antidepressant effect acceleration,  
not recommended for augmentation
Stimulants81 Negative RCTs 81 May have a role for adjunctive treatment of apathy. 
Accelerates the antidepressant effect
Sex hormones Mixed data, most for testosterone Significant long-term side effects
Atypical antipsychotics
Aripiprazole89 3 positive RCTs,89 FDA indication Negative self-report outcomes
Olanzapine/fluoxetine23 One positive RCT,23 multiple equivocal  
RCTs,85 FDA indication
weight gain, metabolic syndrome
Quetiapine99 One negative RCT, two positive unpublished  
RCTs with extended-release formulation
weight gain, metabolic syndrome, helpful adjunctive  
agent for some patients with TRD but  
placebo-controlled trials are needed
Risperidone96 Two positive RCTs, one negative Trials with short treatment lead-in  
(4–5 weeks on previous antidepressant treatment)
Ziprasidone85 Mixed open-label data only85
All antipsychotics Response (odds ratio = 1.69) and  
remission (odds ratio = 2.00) versus  
placebo from RCTs
Discontinuation rates for adverse events higher versus 
placebo (odds ratio = 3.91)
Note: information sourced from a number of papers.11,13–14,23,31,77–98,100
Abbreviations: RCTs, randomized controlled trials; FDA, Food and Drug Administration; SSRi, selective serotonin reuptake inhibitor; STAR*D, Sequenced Treatment 
Alternatives to Relieve Depression; TRD, treatment-resistant depression.
of patients with unipolar and bipolar treatment-resistant 
depression (n = 49) were reported to have at least one other 
Axis I and two additional Axis I diagnoses, respectively, 
which included anxiety disorder and substance abuse. Axis 
I comorbidity appears to be differentially associated with 
treatment resistance in unipolar and bipolar depression.101 
It is also true with treatment-resistant depression, which is 
probably associated with a variety of physical diseases at an 
etiological level, including painful syndromes.102 In addition, 
both physical and psychiatric comorbid conditions contribute 
to treatment resistance in patients with depression. Patients 
with comorbidities who showed a partial response to TCA, 
monoamine oxidase inhibitors, SSRI, and SNRI may derive 
benefit from the use of stimulants, ie, methylphenidate 10 mg 
three times daily, dextroamphetamine 5 mg three times 
daily, or modafinil 100–200 mg once daily. These medica-
tions are reported to accelerate the effects of antidepressant 
therapy, but have a potential for abuse and randomized 
controlled trials failed to produce any treatment benefits.76,81 
However, these medications may have a role in the adjunctive 
treatment of apathy.30,81 Nefazodone, another compound used 
concurrently with prescribed medications in patients with 
treatment-resistant depression (n = 20) and high psychiatric 
comorbidity (post-traumatic stress disorder, substance use 
disorder, and personality disorder) produced good results, 
with 50% of patients (n = 11) showing substantial improve-
ment, and a smaller proportion having a more modest clini-
cal response.84 Duloxetine and venlafaxine have also been 
used in several studies with fairly good results.103 The basic 
principles of treating treatment-resistant depression with 
comorbidities remain the same and all options need to be 
used sequentially.104
Electroconvulsive therapy
ECT is a recognized mode of treatment for a variety of mental 
disorders, including treatment-resistant depression.105,106 
ECT is still the most consistently effective in patients 
with treatment-resistant depression, with a response rate 
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of 50%–70%.30 Furthermore, ECT remains the treatment 
of first choice for the most severe, incapacitating forms of 
treatment-resistant depression, though the strength of the 
recommendation of ECT is level C.78 Surprisingly, relapse 
rates are significantly higher in patients with treatment-
resistant depression after a successful course of therapy.107 
Research is needed to establish the efficacy of alternative 
methods to prevent relapse following successful ECT, includ-
ing maintenance ECT and combination pharmacotherapy 
strategies. Patients who fail to respond to ECT as proposed 
in Stage 5 treatment-resistant depression represent some 
of the most challenging cases. Predictors of nonresponse 
to ECT need to be in place. In a large patient population 
with treatment-resistant depression, ECT was an effective 
treatment for approximately two thirds of cases. A lack of 
response to ECT was associated with bipolar subtype, pres-
ence of manic symptoms during depression, slightly less 
severe depressive symptomatology, and protracted duration 
of the depressive episode.108 In a recent study of adolescents 
with treatment-resistant depression, continuation ECT and 
maintenance ECT were useful and safe treatment strategies 
for selected adolescents with severe treatment-resistant 
depression, and symptom remission was achieved without 
cognitive impairment.109
Other somatic therapies
These reversible but more invasive therapies were developed 
to avoid the adverse effects and complications of ECT and 
at the same time to be more effective in treatment-resistant 
  depression. rTMS and VNS are approved by the US Food 
and Drug Administration for the treatment of intractable sei-
zure disorders and treatment-resistant depression. However, 
with regard to treatment-resistant depression, other neu-
romodulation therapies, including DBS, magnetic seizure 
therapy, and tDCS, are in the experimental stages.30,88,110–112 
Notably, the Food and Drug Administration has approved 
DBS for compassionate use in severe obsessive-compulsive 
disorder.
Studies of somatic therapies seem to be producing 
promising results. In an open-label study, 21 patients who 
failed two antidepressant trials were given rTMS therapy 
(high-frequency, 10 Hz, intensity of 110%) for 4 weeks, 
keeping the dose of pre-existing antidepressants unchanged. 
Nineteen patients completed the study and were assessed. 
In intention-to-treat analysis, the mean HRSD-17 scores 
were reduced from 30.80 ± 5.00 to 19.00 ± 6.37. Only four 
patients reported headache, but there was no discontinuation 
due to adverse effects. The study indicated the potential 
utility of rTMS as an augmenting agent in treatment-
resistant depression. Both high frequency left-sided and 
low frequency right-sided unilateral rTMS are efficacious 
in treatment-resistant depression. Similar benefits have been 
suggested for sequential bilateral rTMS (low frequency 
right-sided then high frequency left-sided).113 In another 
study, subjects aged 18–85 years were recruited from a 
tertiary care university hospital. Seventy-four subjects with 
treatment-resistant depression and a 17-item HRSD score 
greater than 21 were randomized to receive unilateral, bilat-
eral, or sham rTMS. The rates of remission were compared 
between the three treatment groups. The remission rates 
differed significantly between the groups using a modified 
intention-to-treat analysis that excluded subjects who did 
not respond to ECT during the current episode. The remis-
sion rate was significantly higher in the bilateral group than 
in the sham group. The remission rate in the unilateral group 
did not differ in either group.114 These studies, including a 
meta-analysis, call for larger controlled studies to compare 
the efficacy of sequential bilateral rTMS and high frequency 
Table 6 Mechanism of action of agents used as augmentation for 
treatment-resistant depression
Augmentation agent Mechanism of action
Lithium Potentiate serotonergic neurotransmission, 
modulates phosphatidyl-inositol pathway
Triiodothyronine Potentiate norepinephrine neurotransmission,   
corrects subclinical hypothyroidism that 
causes depression-like symptoms
Atypical antipsychotics improve frontal serotonin, norepinephrine, 
and dopamine functions, and other 
neurotransmitters such as glutamate
Psychostimulants improve norepinephrine and dopamine 
neurotransmission
inositol Precursor of diacylglycerol and inositol 
triphosphate
Estrogen Affects gamma aminobutyric acid, 
serotonergic, noradrenergic and cholinergic 
neurotransmission
Omega-3 fatty acids Normalize communication in nerve cells; 
lower tumor necrosis factor-α; lower 
interleukin-B; lower prostaglandins  
E 2, 3, 4; and increase brain-derived  
neurotrophic factor
Dopamine agonists increase dopamine tone
Herbal supplements May impact monoaminergic 
neurotransmission
Lamotrigine Blocks 5-hydroxytriptamine 3 receptors, 
potentiates dopamine
Tetraiodothyronine Potentiates norepinephrine 
neurotransmission
Pindolol increases serotonergic tone
Copyright © 2005, MBL Communications. Adapted with permission from Gotto J, 
Rapaport MH. Treatment options in treatment-resistant depression. Prim Psychiatry. 
2005;12:42–50.46
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left-sided rTMS in depression and treatment-resistant 
depression.114,115
In another study, 22 patients with major depression were 
randomly assigned to a crossover protocol comparing tDCS 
and placebo stimulation add-on to a stable antidepressant 
medication. The parameters of active tDCS were: 1 mA or 
2 mA for 20 minutes daily, with the anode over the left dorso-
lateral prefrontal cortex and the cathode over the contralateral 
supraorbital region. Active and placebo tDCS was applied for 
2 weeks using indistinguishable direct current stimulators. 
Patients, raters, and operators were blinded to the treatment 
conditions. The results showed that there was no significant 
difference in depression scores after 2 weeks of real tDCS 
compared with 2 weeks of sham tDCS. However, subjective 
mood ratings showed an increase in positive emotions after real 
tDCS compared with sham tDCS. Anodal tDCS, applied for 2 
weeks, was not superior to placebo in patients with treatment-
resistant depression. A modified and improved tDCS protocol 
should be investigated in controlled pilot trials to develop 
effective tDCS for treatment-resistant depression.116
In an interesting single treatment-resistant depression 
patient analysis, VNS produced good results and achieved a 
cost saving over modified ECT.117 Both ECT and VNS could 
be combined in managing severe cases of treatment-resistant 
depression. VNS has some disadvantages, including hoarse-
ness of voice caused by the stimulator delivering the electri-
cal pulse, and rarely infection due to surgical implantation 
of a small device into the left chest wall.117 In an open-label 
study of resistant major depressive episode, the predictors of 
response to VNS were a history of resistant depression, mild 
to moderate resistant depression, non-severe resistant depres-
sion, and no history of use of ECT.118 The long-term effects 
and tolerability of VNS need to be determined to ascertain 
its suitability for use in treatment-resistant depression.
A multicenter pilot study of 21 patients with treatment-
resistant depression who received DBS found that patients 
treated with subcallosal cingulate gyrus DBS had an 
RESP50 of 57% at one month, 48% at 6 months, and 29% 
at 12 months. However, the response rate after 12 months 
of DBS increased to 62% when response is defined by 50% 
reduction in baseline HRSD-17 score (RESP50). Reductions 
in depressive symptoms were associated with amelioration 
of disease severity in patients who responded to surgery. 
Overall, findings from this study corroborated the results 
of previous reports showing that outcome of subcallosal 
cingulate gyrus DBS may be replicated across centers.119 
Ward and Irazoqui have provided greater detail on target 
structures, motivation, response rates, and the proposed 
mechanism of action of somatic therapies used in treatment-
resistant depression.4 Data from a follow-up study suggested 
that in the long term (up to 6 years), DBS remains a safe 
and effective treatment for treatment-resistant depression.120 
Finally, psychosurgery, such as subcaudate tractotomy, limbic 
leucotomy, anterior capsulotomy, and anterior cingulotomy 
remain the last line of somatic treatment for patients with 
severe treatment-resistant depression.30
Table 7 Dosing strategies for augmentation agents for treatment-resistant depression
Augmentation agents Recommended dosing strategies Side effects
Lithium initially 150 mg twice daily to be increased in accordance  
with blood level (0.4–0.8 mEq/L) and clinical response
Tremors, weight gain, polydipsia, polyurea
Triiodothyronine 25–50 µg/day for 3 weeks irritability, sweating, palpitation, and anxiety
Olanzapine 2.5–5 mg/day Sedation and weight gain
Ziprasidone 20–40 mg/day Sedation and weight gain
Risperidone 0.5–1 mg/day Sedation and weight gain
Methylphenidate 5–30 mg/day insomnia, irritability, Gi symptoms, abuse 
and blood pressure/heart rate variability
Dextroamphetamine 10–20 mg/day insomnia, irritability, Gi symptoms, abuse 
and blood pressure/heart rate variability
Modafinil 200 mg/day Headache, dizziness, nausea and dry mouth
Primapexole 0.25–2.5 mg/day Nausea and agitation
inositol 500–1000 mg/day Not available
Estrogen 0.1–0.2 mg patch Risk for breast and uterine cancer,  
weight gain, and edema
Omega-3 fatty acids 6 g EPA and 2 g DHA Unpleasant fishy burp
Lamotrigine 12.5–25 mg/day initially; increase by 12.5–25 mg/week  
up to 100–220 mg/day
Nausea, headache, blurry vision,  
rash and sleepiness
Notes: Pindolol, T4, and herbal supplements are not recommended.
Copyright © 2005, MBL Communications.  Adapted with permission from Gotto J, Rapaport MH.  Treatment options in treatment-resistant depression. Prim Psychiatry. 2005;12:42–50.46
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Gi, gastrointestinal. 
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Complementary and alternative 
medicine
The therapeutic role of ethyl eicosapentaenoic acid, an 
essential fatty acid, as an augmentation agent for traditional 
antidepressants in treatment-resistant depression has been 
reported.30 Puri et al showed that eicosapentaenoic acid 
improved some symptoms, including suicidal ideation and 
social phobia, in a single patient with severe treatment-
resistant depression. This compound also induced neurobio-
logical changes, such as a 30% increase in the volumetric 
niacin response, a 53% increase in the relative concentration 
of cerebral phosphomonoesters, a 79% increase in the ratio 
of cerebral phosphomonoesters to phosphodiesters, and a 
reduction in the lateral ventricular volume of the brain.121 
The therapeutic value of L-methylfolate, a medicinal food, 
is emphasized in patients of Hispanic origin with treatment-
resistant depression.122 The efficacy of other complementary 
and alternative medicines in patients with treatment-resistant 
depression needs to be studied because these therapies 
have minimal adverse effects and their contribution to 
the management of various diseases is expanding rapidly. 
Conversely, in modern medicine, of about 65% of patients 
who discontinue antidepressants, 45% of them do so because 
of unpleasant side effects.123 Regarding lifestyle changes, 
researchers reported positive effects of moderate physical 
exercise on quality of life in patients with treatment-resistant 
depression.124
Psychotherapy
In general, psychotherapy alone is effective in mild to moder-
ate depression, and when combined with antidepressants, is 
associated with better results in severe depression than either 
therapy alone. Traditionally, the strength of recommenda-
tion for psychotherapy is B level, and it has been considered 
useful in the management of treatment-resistant depression, 
primarily as an adjunct to help patients maintain morale and 
optimism.78 Currently, various studies have also justified the 
use of psychotherapy, especially cognitive behavior therapy, 
when using switching and augmentation approaches in 
patients with treatment-resistant depression.9,30,100 In a com-
parative study that recruited patients with treatment-resistant 
depression who responded unsatisfactorily to citalopram and 
were assigned randomly to either augmentation of citalopram 
with cognitive therapy or sustained-release bupropion or 
buspirone or switch to cognitive therapy or another antide-
pressant, sertraline, sustained-release bupropion, or extended-
release venlafaxine, Thase et al100 found that pharmacologic 
augmentation was more rapidly effective than augmentation 
of citalopram using cognitive behavioral therapy, whereas 
switching to cognitive behavioral therapy was better tolerated 
than switching to a different antidepressant. Few randomized 
controlled trials125,126 have investigated interventions for 
treatment-resistant depression in young people, and results 
from these show modest benefit from antidepressants, with 
no additional benefit of cognitive behavioral therapy over 
medication. Overall, there is a lack of evidence about effec-
tive interventions to treat young people who have failed to 
respond to evidence-based interventions for depression. 
Research in this area is urgently required.125,126 In a related 
development, research suggests that children and adolescents 
with school difficulties are less likely to respond to fluoxetine 
compared with those with no school difficulties. Depressed 
adolescents in the Treatment of Resistant Depression in 
Adolescents study, who had not responded to a previous 
adequate trial of an SSRI, were randomly assigned to one 
of the following: another SSRI, venlafaxine, another SSRI + 
cognitive behavioral therapy, or venlafaxine + cognitive 
behavioral therapy. Participants were classified into four 
groups, depending on whether their enrollment in the study 
and end of treatment was during school or summer vacation. 
There was a significant interaction between school difficulties 
and timing of treatment, with the lowest rates of response 
being among adolescents having school difficulties and 
ending their treatment during the active school year. School 
problems are relevant to treatment response in depressed 
adolescents and should be incorporated into the treatment 
plan. These findings also suggest that the time of year might 
need to be taken into consideration for analysis of clinical 
trials in school-aged youth.127 In a systematic review,128 
researchers examined the utility of psychotherapy in the 
management of treatment-resistant depression, and found it 
to be useful. However, the evidence was sparse and the results 
were mixed. Given that quality trials are lacking, rigorous 
clinical trials are recommended to guide practice, including 
in primary care.128
A team of researchers examined the long-term outcome of 
participants in the Treatment of SSRI-Resistant Depression in 
Adolescents, in which 334 adolescents with major depressive 
disorder initially resistant to SSRI treatment were randomly 
treated for 12 weeks with another SSRI, venlafaxine, another 
SSRI + cognitive behavioral therapy, or venlafaxine + cogni-
tive behavioral therapy. Responders then continued with the 
same treatment through week 24, while non-responders were 
given open treatment. By 72 weeks, an estimated 61.1% of the 
randomized adolescents had reached remission. Randomly 
assigned treatment, ie, that given for the first 12 weeks, 
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did not influence the remission rate or time to remission, 
but the group assigned to SSRI had a more rapid decline in 
self-reported depressive symptoms and suicidal ideation than 
those assigned to venlafaxine. Participants with more severe 
depression, greater dysfunction, and alcohol or drug use at 
baseline were less likely to remit. The depressive symptom 
trajectory of the remitters diverged from that of non-remitters 
during the first 6 weeks of treatment. Of the 130 participants 
in remission at week 24, 25.4% relapsed in the subsequent 
year. While most adolescents achieved remission, more than 
one third did not, and one quarter of the patients who remit-
ted experienced a relapse. The investigators suggested more 
effective interventions are needed for patients who do not 
show robust improvement early on in treatment.129
Future treatment options
New drugs approved for the management of depression 
are on the market (Table 8). These medications include 
desvenlafaxine (an SNRI), escitalopram (an SSRI), and a 
reformulation of trazodone (Oleptro™). A number of drugs, 
including riluzole, that act on glutamate receptors and have 
antidepressant activity have also been developed and are 
approved for managing major depression.81,130 Studies have 
explored the role of ketamine, an NMDA antagonist, in treat-
ing treatment-resistant depression and acute suicidal ideation. 
Ketamine appears to have a rapid antidepressant effect, 
within hours or a day, although these effects only last 
for 7–10 days. Patients need to be admitted to hospital to 
receive ketamine intravenously from an anesthesiologist, 
while their vital signs are closely monitored. Ketamine is 
a drug of abuse and induces trance-like or hallucinatory 
states. Like other anesthetics, ketamine also produces mild 
to moderate cognitive side effects. Ketamine treatment 
may be akin to ECT and studying ketamine may reveal 
mechanisms underlying depression and help to identify 
drugs that can be prescribed as antidepressants to a wider 
patient population.131 In a comparative study of 17 patients 
with treatment-resistant depression non-responsive to ECT 
and 23 patients with treatment-resistant depression who had 
not previously received ECT were given a single open-label 
infusion of ketamine 0.5 mg/kg and evaluated using the 
Montgomery-Åsberg Depression Rating Scale at baseline 
(60 minutes before the infusion), as well as at 40, 80, 120, 
and 230 minutes after infusion. Depressive symptoms 
were significantly improved in the ECT-resistant group at 
230 minutes, with a moderate effect size. At 230 minutes, 
the group not exposed to ECT showed significant improve-
ment with a large effect size. Ketamine appears to improve 
depressive symptoms in patients with major depression who 
had previously not responded to ECT. These preliminary 
results warrant further investigation in a larger sample size 
to determine the effectiveness of ketamine in patients with 
depression not responsive to other treatments.132 In one study, 
10 participants with treatment-resistant depression were 
given riluzole, another NMDA antagonist, along with their 
regular antidepressant. After 6–12 weeks, they experienced 
an almost 10-point drop on the HRSD.130
Triple reuptake inhibitors that block the reuptake of 
serotonin, norepinephrine, and dopamine, are the newest 
drugs in the stable of monoamine antidepressants.133 
Currently, there are no randomized controlled trials on these 
agents and research is preliminary. It is believed that triple 
reuptake inhibitors devoid of an effect on sexual function 
could be used as second-line treatment when patients with 
depression do not respond to an SSRI.134,135 Non-conventional 
antidepressants, such as tianeptine, are also used for treatment-
resistant depression with some benefits.133 Another new drug, 
agomelatine, the first melatonergic antidepressant containing 
a 5-HT2C receptor antagonist and a melatonin-1 agonist, is 
approved in Europe to treat major depression. It has a unique 
mechanism of action by targeting the melatonin system in 
the brain,81and randomized controlled trials in the treatment-
resistant depression population are needed. In another 
Table 8   Future  treatment  options  for  treatment-resistant 
depression
Medication/intervention Comments
Melatonin drugs  
(agomelatine)
Preliminary data only, no inclusion of 
TRD population in registration trials, 
not yet studied as an augmenting agent
Acetylcholine drugs  
(scopolamine, mecamylamine,  
varenicline)
intravenous infusions used for 
scopolamine, studied as augmenting 
agents rather than primary treatment, 
small numbers in published results, 
large trials underway
Glutamate drugs  
(ketamine, NR2 antagonists,  
riluzole)
Short-term symptomatic relief, only 
intravenous infusions used, further 
trials underway
Neurostimulation vNS approved for TRD but long-term 
treatment needed, TMS showed less 
efficacy in more treatment-resistant 
patients but use of TMS in TRD under 
investigation, DBS trials underway
Copyright © 2010, informa Healthcare. Adapted with permission from Philip NS, 
Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant 
depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;11: 
709–722.81
Abbreviations: NR2, NMDA receptor subunit; TRD, treatment-resistant depression; 
vNS, vagus nerve stimulation; DBS, deep brain stimulation; TMS, transcranial magnetic   
stimulation.
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development, loss of brain-derived neurotrophic factor was 
found in major depression. Brain-derived neurotrophic factor 
is a member of the nerve growth factor family, which helps 
with the survival and growth of neurons. However, stress 
seems to decrease levels of brain-derived neurotrophic factor. 
Increasing brain-derived neurotrophic factor may be a new 
strategy for developing new antidepressants. Furthermore, 
compounds that influence the endocannabinoid system 
involved in depression, and neuropeptide systems, such 
as galanin and melanin-concentrating hormone, may be 
used in the treatment of treatment-resistant depression.133 
Several neuropeptides and their receptors have also been 
identified as potential targets for pharmacologic intervention 
by corticotropin-releasing factor and substance P.136 Some 
investigators have suggested use of Sertoli cell therapy in 
patients with treatment-resistant depression.137 Acetylcholine 
drugs, such as scopolamine, mecamylamine, and varenicline, 
have been used in small studies involving patients with 
treatment-resistant depression, with positive results.81,138,139
In summary, preliminary data for the aforementioned 
newer antidepressant therapies support the view that larger, 
randomized, controlled studies are needed in future. A step-
wise treatment algorithm for patients with treatment-resistant 
depression need to be used for better decision-making, better 
responses, and a higher remission rate in the population with 
treatment-resistant depression.11,140
Discussion
This paper is a narrative review of the literature on treatment-
resistant depression. In addition to Google Scholar and 
Quertle database searches, multiple rounds of computer 
searching of PubMed using key words and a combined 
strategy might have led to some relevant articles, especially 
in young and elderly populations, having been missed, and 
possibly biasing our results. However, the astronomical 
database on treatment-resistant depression published regu-
larly and globally is difficult to synthesize. Furthermore, 
selection and review of all articles by a lone author is an uphill 
task and selection bias might have entered into this qualitative 
review. Despite these caveats, this review reports important 
findings and developments in the therapeutic paradigms 
for treatment-resistant depression over two decades. The 
prevalence of treatment-resistant depression is 10%–30%,7 
but some researchers have suggested that it could be more 
than 30%,11,12,69 according to definitions of treatment-resistant 
depression and other methodological issues. With advances 
in the treatment of resistant depression, it is not surprising 
that its prevalence would temporally decrease or change.
It seems that depression should only be considered drug-
resistant after at least 6 weeks of two trials of antidepressant 
therapy.9,51 Some researchers suggested extending this period 
for up to 10–12 weeks in patients who respond partially to 
trials of antidepressant therapy.15,47 Nonetheless, at least 30% 
of patients continue to manifest residual symptoms with 
poor quality of life and impairment in overall functioning.51 
In addition to requiring several recommended therapeutic 
options, this core group of patients with treatment-resistant 
depression warrants a comprehensive search for factors 
responsible for the persistence of depression, which include 
but are not limited to the patient’s characteristics and 
environment, including stresses, a comorbid psychiatric 
or somatic disorder, and drug abuse or addiction.19,40–42,44,45 
Arguably, the suggested therapeutic strategies for treatment-
resistant depression have variable outcomes in terms of 
response and remission rate, as well as disadvantages due 
to multiple factors, including the adverse effect profile of 
antidepressants.
It is reported that optimization of a first-line antidepressant 
in adequate doses and for an extended period of up to 12 weeks 
is based on weak evidence.19,69,81 Similarly, trials comparing 
continuation of the first-line antidepressant versus switching 
to another antidepressant from a different class have reported 
conflicting results.9,19 A switching strategy may benefit a 
small proportion of patients, but the elimination half-life of 
the discontinued drug, such as fluoxetine, and washout period 
must be taken into account to limit the risk of interactions 
during the transition period.9,19,69,81 A combination approach 
also has some disadvantages because it increases the risk 
of adverse effects, possibly without a substantial clinical 
benefit.19 Evidently, a second course of antidepressant 
monotherapy tends to treat up to 50% of those who have failed 
with the initial treatment effectively, when the second drug 
has a profile distinct from the initial medication. It means that 
25% of patients with treatment-resistant depression respond 
to optimization and combined strategies, and another 50% 
tend to respond to switching options. The remaining 25% of 
patients with treatment-resistant depression are candidates 
for augmentation strategies.81
The strength of evidence supporting a trial of aug-
mentation or a switch to a new agent is very similar, with 
remission rates of 25%–50% in both cases.141 A review of 
comparative trials suggested that adjunctive use of lithium 
and thyroid hormone have an established antidepressant 
effect in patients with treatment-resistant depression, but 
there is no firm evidence that adding lithium to non-TCA 
treatment increases the chances of remission.78,91,93,96,141 
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According to other researchers, thyroid hormone, a benzodi-
azepine, buspirone, and pindolol as augmenting agents have 
limited proven antidepressant effects.19,78,94,96 Furthermore, 
Connolly and Thase141 as well as others 46,78,96 have reported 
that of these two options, ie, lithium versus thyroid hormone, 
T3 augmentation seems to offer the best benefit/risk ratio for 
augmentation of modern antidepressants. However, lithium 
is known to have a narrow therapeutic window and needs 
blood level monitoring to avoid the toxicity and fatalities 
associated with high lithium levels.77,78,80 With regard to 
newer generations of antidepressants, after failure of a 
first-line SSRI, neither a switch within a class nor a switch 
to a different class of antidepressant is unequivocally sup-
ported by the data, although switching from an SSRI to 
venlafaxine or mirtazapine may potentially offer greater 
benefits.75–77,141 In an open-label study, mirtazapine was 
effective in 38% of patients with depression resistant to 
standard   antidepressants.142 It is noted that switching from 
a newer antidepressant to a TCA after a poor response to the 
former is not supported by strong evidence.142 Augmentation 
with an antiepileptic or a psychostimulant is not supported 
unequivocally but they are reported to be more harmful 
than beneficial because of adverse effects, including the 
addiction potential of stimulants.46,81,96–98 Conversely, the 
use of psychostimulants with conventional antidepressants 
is recommended in patients with treatment-resistant depres-
sion because significant improvement was demonstrated, in 
particular with respect to energy, mood, and psychomotor 
activity. It was concluded that their rapid onset of action 
(2–3 hours) after administration may help cover the thera-
peutic latency period of conventional antidepressants and 
probably potentiates their effect.143 According to some stud-
ies, augmentation with atypical antipsychotics has had mixed 
results,23,85,96 but quetiapine and aripiprazole were relatively 
supported by the evidence.89,99 It is noted that Symbyax®, a 
combination of olanzapine and fluoxetine, is approved for 
the acute management of treatment-resistant depression.
ECT has a place in the management of patients fail-
ing multiple optimized monotherapies, switching options, 
combined approaches, and augmented treatment strate-
gies30,105,106,108 but carries a risk of reversible memory 
disorders.19 Surprisingly, patients with treatment-resistant 
depression who responded to ECT were found to have a high 
relapse rate,107 which could be prevented by maintenance 
ECT. Some studies reported no cognitive impairment with 
ECT in adolescents with treatment-resistant depression.109 
In this regard, replication research is required to support or 
refute such results. The role of other somatic interventions, 
including VNS, rTMS, DBS, and tDCS, in patients with 
treatment-resistant depression is expanding with greater 
efficacy, but have some side effects and need further research, 
especially large controlled randomized studies targeting 
particular areas in the brain implicated in major depression 
and treatment-resistant depression.4,112–120 The efficacy of 
psychotherapy in patients with treatment-resistant depression 
is fairly good, and 50% of patients tend to get benefits from 
psychotherapies, especially cognitive behavioral therapy 
and mindfulness-based cognitive behavioral therapy.19,100,144 
Additional cognitive behavioral therapy in the young popu-
lation with treatment-resistant depression has limited or no 
value and needs further research.126 Regular exercise and use 
of some complementary and alternative medicines impact 
positively on treatment-resistant depression and need further 
research using herbal supplements.124
Conclusion
In summary, 70% of patients with major depression respond 
to initial antidepressant therapy, leaving 30% of patients 
who are refractory to treatment and therefore need special 
treatment-resistant depression management strategies. 
Twenty-five percent of patients with treatment-resistant 
depression tend to respond to optimization and combined 
treatment paradigms and another 50% of patients are reported 
to respond to switching therapeutic options. Augmentation 
strategies target the remaining 25% of patients suffering from 
treatment-resistant depression, with inconsistent outcomes. 
Overall, although there is no strict compartmentalization of 
treatment response and remission rate in the population with 
treatment-resistant depression, about one third of patients 
with the disorder continue to be resistant to available thera-
peutic options, and hence pose a major therapeutic challenge 
to mental health experts.
Recommendations
Based on this narrative review, that has some caveats, the 
following recommendations are made:
•	 Each individual with treatment-resistant depression is a 
unique case and needs detailed evaluation to identify the 
prior antidepressant response and also to make a correct 
diagnosis.
•	 Assessment of risk factors for treatment-resistant 
depression is equally important to guide mental health 
professionals in tailoring an appropriate management plan 
for patients with treatment-resistant depression.
•	 There are a wide variety of options for the treatment of 
major depression and treatment-resistant depression, 
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therefore every therapeutic paradigm needs to be 
utilized when helping patients with treatment-resistant 
depression.
•	 In light of the demonstrated importance of truly adequate 
treatment to the long-term outcomes of patients with 
treatment-resistant depression, further randomized clini-
cal trials involving newer drugs and psychotherapies and 
somatic therapies are needed in the future.
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